Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent discussed cardio-oncology networks for patients, emphasizing the importance of establishing a framework where the expertise of the cardiology consultant can supplement and reinforce the goals of optimal cancer therapy. Professor Thomas Suter moved the discussion further, sharing his insight into cardiac monitoring in clinical trials, emphasizing the lack of uniform criteria and lack of consensus regarding reversibility of cardiac events and long-term implications of modest declines in systolic function frequently found in clinical trials for which long-term follow-up may not be a component of the trial. Professor Giorgio Minotti added important considerations to the discussion of clinical trials. He emphasized that the usual reporting of cardiac systolic function omits important diastolic dysfunction data generated but often ignored during the routine cardiac exams. The inclusion of cardiac biomarker changes would also help to broaden the perspective of cardiac effects and events seen in patients enrolled in clinical trials.

中文翻译：

---

心脏肿瘤学在临床研究和现实生活中的应用。

座谈会第五场由西班牙的TeresaLópez-Fernández教授和波兰的Grzegorz Opolski教授主持。3位演讲者讨论了与临床研究和现实生活相关的心脏病学问题。Susan Dent教授讨论了针对患者的心血管系统网络，并强调了建立一个框架的重要性，心脏病专家的专业知识可以以此框架来补充和加强最佳癌症治疗的目标。托马斯·苏特（Thomas Suter）教授进一步推动了讨论，并分享了他对临床试验中心脏监测的见解，强调缺乏统一的标准，缺乏关于心脏事件可逆性的共识，以及临床试验中经常发现的收缩功能适度下降的长期影响，而长期随访可能不属于该试验的组成部分。Giorgio Minotti教授在临床试验的讨论中增加了重要考虑因素。他强调，常规的心脏收缩功能报告会忽略重要的舒张功能障碍数据，但在常规心脏检查中经常会忽略这些数据。包括心脏生物标志物变化也将有助于拓宽临床试验入组患者的心脏效应和事件的视野。他强调，常规的心脏收缩功能报告会忽略重要的舒张功能障碍数据，但在常规心脏检查中经常会忽略这些数据。包括心脏生物标志物变化也将有助于拓宽临床试验入组患者的心脏效应和事件的视野。他强调，常规的心脏收缩功能报告会忽略重要的舒张功能障碍数据，但在常规心脏检查中经常会忽略这些数据。包括心脏生物标志物变化也将有助于拓宽临床试验入组患者的心脏效应和事件的视野。